Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 May;84(5):440–443. doi: 10.1136/adc.84.5.440

Short stature in Noonan syndrome: response to growth hormone therapy

J Kirk 1, P Betts 1, G Butler 1, M Donaldson 1, D Dunger 1, D Johnston 1, C Kelnar 1, D Price 1, P Wilton 1, t U Group 1
PMCID: PMC1718750  PMID: 11316696

Abstract

BACKGROUND—Growth hormone (GH) has been used to promote growth in both the short and long term in a number of dysmorphic syndromes, including Turner syndrome. As this condition shares many clinical features with Noonan syndrome, it would seem logical to treat the latter group with GH.
AIMS—To assess the short and long term response to GH therapy in patients with Noonan syndrome.
METHODS—Analysis of patients with Noonan syndrome in the Pharmacia & Upjohn International Growth Study (this post-marketing database contains data on the majority of patients currently treated with GH in the UK). A questionnaire was also sent to participating clinicians.
RESULTS—Data on 66 patients (54 males) were available for study. At the start of GH therapy children were short, compared with both normal and Noonan children. During the first year of GH therapy height velocity increased from a mean of 4.9 to 7.2 cm per year. For patients treated long term with GH, mean height SDS increased from −2.9 pretreatment to −2.6 after one year and −2.3 after five years. Of the 10 patients at near final height, only one had a height above the 3rd centile for normal adults and above the mean for untreated Noonan patients. The mean increment in final height was 3.1 cm (range −1.1 to 6.5cm).
CONCLUSIONS—GH therapy in patients with Noonan syndrome will improve height velocity in the short term. Longer-term therapy results in a waning of effect; initial indications are that final height is not improved substantially in most patients.



Full Text

The Full Text of this article is available as a PDF (137.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed M. L., Foot A. B., Edge J. A., Lamkin V. A., Savage M. O., Dunger D. B. Noonan's syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand. 1991 Apr;80(4):446–450. doi: 10.1111/j.1651-2227.1991.tb11880.x. [DOI] [PubMed] [Google Scholar]
  2. Betts P. R., Butler G. E., Donaldson M. D., Dunger D. B., Johnston D. I., Kelnar C. J., Kirk J., Price D. A., Wilton P. A decade of growth hormone treatment in girls with Turner syndrome in the UK. UK KIGS Executive Group. Arch Dis Child. 1999 Mar;80(3):221–225. doi: 10.1136/adc.80.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cotterill A. M., McKenna W. J., Brady A. F., Sharland M., Elsawi M., Yamada M., Camacho-Hübner C., Kelnar C. J., Dunger D. B., Patton M. A. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. J Clin Endocrinol Metab. 1996 Jun;81(6):2291–2297. doi: 10.1210/jcem.81.6.8964866. [DOI] [PubMed] [Google Scholar]
  4. De Schepper J., Otten B. J., François I., Bourguignon J. P., Craen M., Van der Burgt I., Massa G. G. Growth hormone therapy in pre-pubertal children with Noonan syndrome: first year growth response and comparison with Turner syndrome. Acta Paediatr. 1997 Sep;86(9):943–946. doi: 10.1111/j.1651-2227.1997.tb15175.x. [DOI] [PubMed] [Google Scholar]
  5. Duncan W. J., Fowler R. S., Farkas L. G., Ross R. B., Wright A. W., Bloom K. R., Huot D. J., Sondheimer H. M., Rowe R. D. A comprehensive scoring system for evaluating Noonan syndrome. Am J Med Genet. 1981;10(1):37–50. doi: 10.1002/ajmg.1320100106. [DOI] [PubMed] [Google Scholar]
  6. Lyon A. J., Preece M. A., Grant D. B. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985 Oct;60(10):932–935. doi: 10.1136/adc.60.10.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Municchi G., Pasquino A. M., Pucarelli I., Cianfarani S., Passeri F. Growth hormone treatment in Noonan syndrome: report of four cases who reached final height. Horm Res. 1995;44(4):164–167. doi: 10.1159/000184618. [DOI] [PubMed] [Google Scholar]
  8. Nora J. J., Nora A. H., Sinha A. K., Spangler R. D., Lubs H. A. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child. 1974 Jan;127(1):48–55. doi: 10.1001/archpedi.1974.02110200050007. [DOI] [PubMed] [Google Scholar]
  9. Ranke M. B., Heidemann P., Knupfer C., Enders H., Schmaltz A. A., Bierich J. R. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr. 1988 Dec;148(3):220–227. doi: 10.1007/BF00441408. [DOI] [PubMed] [Google Scholar]
  10. Romano A. A., Blethen S. L., Dana K., Noto R. A. Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. J Pediatr. 1996 May;128(5 Pt 2):S18–S21. doi: 10.1016/s0022-3476(96)70005-7. [DOI] [PubMed] [Google Scholar]
  11. Sharland M., Burch M., McKenna W. M., Paton M. A. A clinical study of Noonan syndrome. Arch Dis Child. 1992 Feb;67(2):178–183. doi: 10.1136/adc.67.2.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tanaka T. Growth hormone treatment in Noonan syndrome. Acta Paediatr Jpn. 1996 Feb;38(1):99–101. doi: 10.1111/j.1442-200x.1996.tb03446.x. [DOI] [PubMed] [Google Scholar]
  13. Tanner J. M., Whitehouse R. H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child. 1966 Dec;41(220):613–635. doi: 10.1136/adc.41.220.613. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES